There is no comprehensive umbrella review exploring the connection between
schizophrenia and various health outcomes. Therefore, we aimed to systematically review …

Abstract Purpose of Review Despite clear evidence that sex differences largely impact the
efficacy and tolerability of antipsychotic medication, current treatment guidelines for …

Purpose Antipsychotic-induced prolactin elevation may impede protective effects of
estrogens in women with schizophrenia-spectrum disorders (SSD). Our study sought to …

Bipolar disorders (BDs) are a heterogeneous group of severe affective disorders generally
described by the alternation of (hypo) manic, depressive, and mixed phases, with euthymic …

The current primary therapeutic approach for schizophrenia is antipsychotic medication, and
antipsychotic-induced hyperprolactinemia occurs in 40–80% of patients with schizophrenia …

Long-acting injectable antipsychotics (LAIs) are primarily used for relapse prevention, but in
some settings and situations, they may also be useful for acute treatment of schizophrenia …

Background and aim Available evidence suggests elevated serum prolactin (PRL) levels in
olanzapine (OLZ)-treated patients with schizophrenia. However, machine learning (ML) …

Aim This study identified discrepant therapeutic outcomes of antipsychotics. Methods A total
of 5191 patients with schizophrenia were enrolled, 3030 as discovery cohort, 1395 as …

Hyperprolactinemia and metabolic disturbance are common side effects of antipsychotics
that cause intolerance. Despite its potential influence on relapse, there are no established …

The metabolic syndrome (MetS) is a clustering of abdominal obesity, hypertension,
hyperglycaemia, hypertriglyceridemia and low high‐density lipoprotein (HDL) level. MetS …